Linezolid-Induced Thrombocytopenia in Patients with Renal Impairment: A Case Series, Review and Dose Advice
Drugs in R&D · 2024
DOI: 10.1007/s40268-024-00458-6 ↗Kurz gefasst
Fallbericht in der Zeitschrift Drugs in R&D, 2024. Verfasst von S R E Laarhuis und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Catharina Hospital Eindhoven, Michelangelolaan 2, 5623 EJ, Eindhoven, The Netherlands. slaarhuis@sahz.nl. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Linezolid, Renal Insufficiency, Thrombocytopenia. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVE: Oral linezolid is often used as alternative therapy for intravenous vancomycin. According to the current guidelines, no dose adjustment has to be made in case of renal impairment. Nevertheless, in our hospital we have seen several patients with renal impairment who developed linezolid-induced thrombocytopenia when linezolid was taken in the standard dose. In this case series and review we want to emphasize the necessity of reviewing the Dutch and international guidelines. METHODS: We describe five cases with renal impairment that developed linezolid-induced thrombocytopenia in our hospital. A PubMed literature review was conducted to identify other cases and find the optimal dosing regimen for these patients. RESULTS: Our cases join a long list of cases and available literature about linezolid-induced thrombocytopenia in patients with renal impairment. Less linezolid-induced thrombocytopenia was found, both in our cases and in the literature, after dose reduction of 50%. High linezolid trough concentrations were associated with a higher risk of linezolid-induced thrombocytopenia. Besides renal impairment, other risk factors for developing linezolid-induced thrombocytopenia were also identified, such as low body weight, high daily dose/kg, higher age, longer duration of therapy, low baseline count, malignity, low-dose aspirin and interacting co-medication. CONCLUSION: Re-evaluation of the current dose advice is necessary. We advocate for a standard dose reduction to 50% after 2 days of standard dosing for all patients with an estimated glomerular filtration of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, Catharina Hospital Eindhoven, Michelangelolaan 2, 5623 EJ, Eindhoven, The Netherlands. slaarhuis@sahz.nl.
- Department of Clinical Pharmacy, Catharina Hospital Eindhoven, Michelangelolaan 2, 5623 EJ, Eindhoven, The Netherlands.
- Department of Internal Medicine/Hemato-Oncology, Catharina Hospital Eindhoven, Michelangelolaan 2, 5623 EJ, Eindhoven, The Netherlands.
- Department of Orthopaedic Surgery, Catharina Hospital Eindhoven, Michelangelolaan 2, 5623 EJ, Eindhoven, The Netherlands.
- Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
Zitieren
APA
Laarhuis, S. R. E., Kerskes, C. H. M., Nijziel, M. R., van Wensen, R. J. A., & Touw, D. J. (2024). Linezolid-Induced Thrombocytopenia in Patients with Renal Impairment: A Case Series, Review and Dose Advice. Drugs in R&D. https://doi.org/10.1007/s40268-024-00458-6
Vancouver
Laarhuis SRE, Kerskes CHM, Nijziel MR, van Wensen RJA, Touw DJ. Linezolid-Induced Thrombocytopenia in Patients with Renal Impairment: A Case Series, Review and Dose Advice. Drugs in R&D. 2024. doi:10.1007/s40268-024-00458-6
BibTeX
@article{Laarhuis2024,
author = {Laarhuis, S R E and Kerskes, C H M and Nijziel, M R and van Wensen, R J A and Touw, D J},
title = {Linezolid-Induced Thrombocytopenia in Patients with Renal Impairment: A Case Series, Review and Dose Advice},
journal = {Drugs in R&D},
year = {2024},
doi = {10.1007/s40268-024-00458-6}
}
EUVIMED